Enter the text here that is the new abstract information for your application. This section must be no longer than 30 lines of text. This proposal is aimed at further developing and applying a general method that allows one to systematically add amino acids with novel physical, chemical and biological properties to the genetic codes of both prokaryotic and eukaryotic organisms. This methodology involves the generation of orthogonal tRNA/aminoacyl-tRNA synthetase (aaRS) pairs that uniquely recognize a noncoding codon and do not cross react with any of the endogenous tRNAs and aminoacyl-tRNA synthetases in the host organism. The amino acid specificity of the aminoacyl-tRNA synthetase is then modified such that it aminoacylates its cognate tRNA with only the desired unnatural amino acid and no endogenous amino acid. Using this method, a large number of structurally diverse unnatural amino acids have been incorporated efficiently and with high fidelity into proteins in response to nonsense and frameshift codons. We now propose to extend these studies in several directions. The first is focused on developing robust, user-friendly methods to genetically encode a large number of these unnatural amino acids in mammalian cell. If successful this effort will significantly expand the scope and impact of this technology. The second effort focuses on the synthesis and in vitro and in vivo characterization of chemically defined antibody conjugates for the treatment of cardiovascular disease and acute myeloid leukemia. These latter efforts should not only pave the way for new or significantly improved therapeutics for major unmet medical needs, they should also provide a generalizable, straightforward approach to create similar classes of antibody conjugates for metabolic, cardiovascular and inflammatory diseases.
The ability to genetically encode unnatural amino acids beyond the common twenty will significantly enhance our ability to manipulate protein structure. The result will be new tools to study protein function in vitro and in vivo. It should also be possible to create homogenous chemically mutated therapeutic proteins for cancer and cardiovascular disease with enhanced activity and improved pharmacology.
|Sun, Sophie B; Schultz, Peter G; Kim, Chan Hyuk (2014) Therapeutic applications of an expanded genetic code. Chembiochem 15:1721-9|
|Lu, Hua; Zhou, Quan; Deshmukh, Vishal et al. (2014) Targeting human C-type lectin-like molecule-1 (CLL1) with a bispecific antibody for immunotherapy of acute myeloid leukemia. Angew Chem Int Ed Engl 53:9841-5|
|Kessel, Christoph; Nandakumar, Kutty S; Peters, Francis B et al. (2014) A single functional group substitution in c5a breaks B cell and T cell tolerance and protects against experimental arthritis. Arthritis Rheumatol 66:610-21|
|Javahishvili, Tsotne; Manibusan, Anthony; Srinagesh, Shaila et al. (2014) Role of tRNA orthogonality in an expanded genetic code. ACS Chem Biol 9:874-9|
|Zhang, Yong; Goswami, Devrishi; Wang, Danling et al. (2014) An antibody with a variable-region coiled-coil "knob" domain. Angew Chem Int Ed Engl 53:132-5|
|Lu, Hua; Wang, Danling; Kazane, Stephanie et al. (2013) Site-specific antibody-polymer conjugates for siRNA delivery. J Am Chem Soc 135:13885-91|
|Zhang, Yong; Wang, Danling; de Lichtervelde, Lorenzo et al. (2013) Functional antibody CDR3 fusion proteins with enhanced pharmacological properties. Angew Chem Int Ed Engl 52:8295-8|
|Sun, Sophie B; Sen, Shiladitya; Kim, Nam-Jung et al. (2013) Mutational analysis of 48G7 reveals that somatic hypermutation affects both antibody stability and binding affinity. J Am Chem Soc 135:9980-3|
|Zhang, Yong; Wang, Danling; Welzel, Gus et al. (2013) An antibody CDR3-erythropoietin fusion protein. ACS Chem Biol 8:2117-21|
|Kazane, Stephanie A; Axup, Jun Y; Kim, Chan Hyuk et al. (2013) Self-assembled antibody multimers through peptide nucleic acid conjugation. J Am Chem Soc 135:340-6|
Showing the most recent 10 out of 83 publications